Ollberry Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.11 M
- Company Age 5 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
- Revenue Growth 174.45%
- Profit Growth 605.96%
- Ebitda 327.44%
- Net Worth 119.62%
- Total Assets 102.92%
About Ollberry Lifesciences
Ollberry Lifesciences Private Limited (OLPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 February 2019 (Five years and 11 months 25 days old ). Its registered office is in Kamrup, Assam, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.11 M.
The company currently has active open charges totaling ₹1.00 M.
Rumi Sarma and Sushanta Paul serve as directors at the Company.
Company Details
-
Location
Kamrup, Assam, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U36999AS2019PTC019031
-
Company No.
019031
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
19 Feb 2019
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Shillong
Industry
Who are the key members and board of directors at Ollberry Lifesciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rumi Sarma
|
Director | 19-Feb-2019 | Current |
|
Sushanta Paul
|
Director | 04-Mar-2022 | Current |
Financial Performance of Ollberry Lifesciences.
Ollberry Lifesciences Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 174.45% increase. The company also saw a substantial improvement in profitability, with a 605.96% increase in profit. The company's net worth Soared by an impressive increase of 119.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ollberry Lifesciences?
In 2021, Ollberry Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Dec 2023 | Others | ₹1.00 M | Open |
How Many Employees Work at Ollberry Lifesciences?
Ollberry Lifesciences has a workforce of 6 employees as of Mar 25, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ollberry Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ollberry Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
